PMID- 36613708
OWN - NLM
STAT- MEDLINE
DCOM- 20230110
LR  - 20230111
IS  - 1422-0067 (Electronic)
IS  - 1422-0067 (Linking)
VI  - 24
IP  - 1
DP  - 2022 Dec 23
TI  - Peripheral Inflammatory Markers TNF-alpha and CCL2 Revisited: Association with 
      Parkinson's Disease Severity.
LID - 10.3390/ijms24010264 [doi]
LID - 264
AB  - One of the major mediators of neuroinflammation in PD is tumour necrosis factor 
      alpha (TNF-alpha), which, similar to other cytokines, is produced by activated 
      microglia and astrocytes. Although TNF-alpha can be neuroprotective in the brain, 
      long-term neuroinflammation and TNF release can be harmful, having a neurotoxic 
      role that leads to death of oligodendrocytes, astrocytes, and neurons and, 
      therefore, is associated with neurodegeneration. Apart from cytokines, a wide 
      family of molecules with homologous structures, namely chemokines, play a key 
      role in neuro-inflammation by drawing cytotoxic T-lymphocytes and activating 
      microglia. The objective of the current study was to examine the levels of the 
      serum TNF-alpha and CCL2 (Chemokine (C-C motif) ligand 2), also known as MCP-1 
      (Monocyte Chemoattractant Protein-1), in PD patients compared with healthy 
      controls. We also investigated the associations between the serum levels of these 
      two inflammatory mediators and a number of clinical symptoms, in particular, 
      disease severity and cognition. Such an assessment may point to their prognostic 
      value and provide some treatment hints. PD patients with advanced stage on the 
      Hoehn-Yahr scale showed an increase in TNF-alpha levels compared with PD patients 
      with stages 1 and 2 (p = 0.01). Additionally, the UPDRS score was significantly 
      associated with TNF-alpha levels. CCL2 levels, however, showed no significant 
      associations.
FAU - Xiromerisiou, Georgia
AU  - Xiromerisiou G
AD  - Department of Medicine, Faculty of Life Sciences, University of Thessaly, 41500 
      Larisa, Greece.
FAU - Marogianni, Chrysoula
AU  - Marogianni C
AUID- ORCID: 0000-0002-5979-9916
AD  - Department of Medicine, Faculty of Life Sciences, University of Thessaly, 41500 
      Larisa, Greece.
FAU - Lampropoulos, Ioannis C
AU  - Lampropoulos IC
AUID- ORCID: 0000-0002-8956-2178
AD  - Respiratory Medicine Department, Faculty of Medicine, University of Thessaly, 
      41500 Larissa, Greece.
FAU - Dardiotis, Efthimios
AU  - Dardiotis E
AUID- ORCID: 0000-0003-2957-641X
AD  - Department of Medicine, Faculty of Life Sciences, University of Thessaly, 41500 
      Larisa, Greece.
FAU - Speletas, Matthaios
AU  - Speletas M
AUID- ORCID: 0000-0003-1287-7734
AD  - Department of Immunology & Histocompatibility, Faculty of Medicine, University of 
      Thessaly, 41500 Larissa, Greece.
FAU - Ntavaroukas, Panagiotis
AU  - Ntavaroukas P
AD  - Department of Biochemistry and Biotechnology, Faculty of Life Sciences, 
      University of Thessaly, 41500 Larisa, Greece.
FAU - Androutsopoulou, Anastasia
AU  - Androutsopoulou A
AD  - Department of Biochemistry and Biotechnology, Faculty of Life Sciences, 
      University of Thessaly, 41500 Larisa, Greece.
FAU - Kalala, Fani
AU  - Kalala F
AD  - Department of Immunology & Histocompatibility, Faculty of Medicine, University of 
      Thessaly, 41500 Larissa, Greece.
FAU - Grigoriadis, Nikolaos
AU  - Grigoriadis N
AUID- ORCID: 0000-0002-4278-3301
AD  - Laboratory of Experimental Neurology and Neuroimmunology, Second Department of 
      Neurology, American Hellenic Educational Progressive Association (AHEPA) 
      University Hospital, Aristotle University of Thessaloniki, 54124 Thessaloniki, 
      Greece.
FAU - Papoutsopoulou, Stamatia
AU  - Papoutsopoulou S
AUID- ORCID: 0000-0001-6665-8508
AD  - Department of Biochemistry and Biotechnology, Faculty of Life Sciences, 
      University of Thessaly, 41500 Larisa, Greece.
LA  - eng
PT  - Journal Article
DEP - 20221223
PL  - Switzerland
TA  - Int J Mol Sci
JT  - International journal of molecular sciences
JID - 101092791
RN  - 0 (Chemokine CCL2)
RN  - 0 (Tumor Necrosis Factor-alpha)
RN  - 0 (Chemokines)
RN  - 0 (Cytokines)
RN  - 0 (CCL2 protein, human)
SB  - IM
MH  - Humans
MH  - *Chemokine CCL2
MH  - *Parkinson Disease/diagnosis
MH  - Tumor Necrosis Factor-alpha
MH  - Neuroinflammatory Diseases
MH  - Chemokines
MH  - Cytokines
MH  - Patient Acuity
PMC - PMC9820450
OTO - NOTNLM
OT  - CCL2
OT  - MCP-1
OT  - Parkinson's disease
OT  - TNF-a
OT  - biomarkers
OT  - inflammation
COIS- The authors declare no conflict of interest.
EDAT- 2023/01/09 06:00
MHDA- 2023/01/11 06:00
PMCR- 2022/12/23
CRDT- 2023/01/08 01:21
PHST- 2022/11/21 00:00 [received]
PHST- 2022/12/18 00:00 [revised]
PHST- 2022/12/19 00:00 [accepted]
PHST- 2023/01/08 01:21 [entrez]
PHST- 2023/01/09 06:00 [pubmed]
PHST- 2023/01/11 06:00 [medline]
PHST- 2022/12/23 00:00 [pmc-release]
AID - ijms24010264 [pii]
AID - ijms-24-00264 [pii]
AID - 10.3390/ijms24010264 [doi]
PST - epublish
SO  - Int J Mol Sci. 2022 Dec 23;24(1):264. doi: 10.3390/ijms24010264.